伏立康唑胶囊预防初诊急性髓系白血病患者侵袭性曲霉菌感染的临床研究

发布时间：2019-02-22 08:47

【摘要】：目的观察伏立康唑在初诊急性髓系白血病(AML)诱导缓解治疗中侵袭性曲霉菌感染一级预防的有效性及安全性。方法初诊急性髓系白血病诱导缓解治疗的96例患者分为试验组66例和对照组30例。试验组患者口服伏立康唑胶囊预防真菌感染,首日为负荷剂量6 mg·kg~(-1),每日2次。次日起维持剂量200 mg,每日2次;对照组患者未进行真菌感染预防。观察2组患者真菌感染的发生率,分析预防用药的有效性和安全性。结果应用伏立康唑胶囊进行真菌感染的一级预防,未发现严重的药物不良反应发生。试验组患者在诱导缓解治疗中侵袭性曲霉菌(IA)感染发生率为0.02%(1/66例),对照组侵袭性曲霉菌感染的发生率为13.33%(4/30例,P0.05)。结论伏立康唑胶囊能有效降低初诊急性髓系白血病患者的侵袭性曲霉菌感染的发生率。
[Abstract]:Objective to observe the efficacy and safety of Volconazole in the primary prevention of invasive aspergillus infection in the treatment of newly diagnosed acute myeloid leukemia (AML). Methods 96 patients with acute myeloid leukemia were divided into trial group (n = 66) and control group (n = 30). Patients in the test group were treated with Volconazole capsule for prevention of fungal infection, the first day was 6 mg kg~ (-1), twice a day. From the next day, the dose of 200 mg, was maintained twice a day, while the control group was not prevented from fungal infection. The incidence of fungal infection was observed and the efficacy and safety of prophylaxis were analyzed. Results Volconazole capsule was used to prevent fungal infection and no serious adverse drug reactions were found. The incidence of invasive Aspergillus (IA) infection was 0.02% (1 / 66 cases) in the trial group and 13.33% (4 / 30 cases, P0.05) in the control group. Conclusion Veconazole capsule can effectively reduce the incidence of invasive aspergillosis in newly diagnosed patients with acute myeloid leukemia.
【作者单位】：厦门大学附属第一医院血液科;福建医科大学附属协和医院血液科;
【基金】：2015年福建省卫生计生委青年科研课题基金资助项目(2015-1-39)
【分类号】：R519.8;R733.71

【相似文献】